Articles On Paradigm Biopharmaceuticals (ASX:PAR)

If your portfolio doesn’t have exposure to the small side of the market, I think it would be well worth considering adding one or two small cap shares to it if your risk profile allows. After all, you only need to look at Altium Limited (A...

There are more than 150 healthcare shares listed on the ASX, varying from pharmaceutical manufacturers, to medical software developers to facility operators. So where should you start if you want to add ASX healthcare shares to your portfo...

The S&P/ASX 200 index is ending the year with a day in the red. In afternoon trade the benchmark index is down a sizeable 1.7% to 6,688.7 points. Four shares that have not let that hold them back today are listed below. Here’s why they...

A new year is upon us, so what better time to look at potential new additions to your portfolio. If you’re interested in gaining a little exposure to the small side of the market, then the three ASX shares listed below could be the ones to...

Due to populations around the world getting older and chronic disease burden increasing, demand for healthcare services continues to rise. I believe this trend will continue for several decades, which could make the healthcare sector a gre...

On Christmas Day I picked out 10 top ASX shares that I think could be great options for investors in 2020. But they weren’t the only shares that I would be buying right now. Here are 10 more top ASX shares to own in 2020: Nearmap Ltd (ASX:...

In late trade S&P/ASX 200 index is having a subdued end to the day ahead of the Christmas break. At the time of writing the benchmark index is flat at 6,786.7 points. Four shares that are out of form on Tuesday are listed below. Here’s...

I think the Australian share market is home to a large number of small cap shares that have the potential to grow materially larger in the future. While history shows that not all small caps deliver on their potential, I think many of thes...

In afternoon trade the S&P/ASX 200 index has come under pressure and is trading notably lower. At the time of writing the benchmark index is down 0.75% to 6,701.9 points. Four shares that have fallen more than most today are listed bel...

With progress to secure regulatory approvals underway for its flagship Zilosul treatment Paradigm Biopharmaceuticals (ASX: PAR) is also gearing up for phase 2/3 clinical trial in the first quarter of next year. Paradigm is preparing for a j...

In morning trade the Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is sinking lower despite the release of its end of year update. At the time of writing the biopharmaceutical company’s shares are down 4% to $3.00. What was in Par...

Paradigm will be meeting with the US FDA in Feb 2020 for a pre-IND meeting among other things.

The S&P/ASX 200 index has returned to form and is pushing higher this afternoon. At the time of writing the benchmark index is up 0.4% to 6,732.4 points. Four shares that have failed to follow the market higher today are listed below....

Paradigm Biopharmaceuticals Ltd (ASX: PAR) shares are up from 99 cents on New Year’s day 2019 to $3.49 today and even hit as high as $4.12 last November. What does Paradigm do? With its shares up 250% in less than a year you’d think Paradi...

The S&P/ASX 200 index has followed the lead of U.S. markets and is dropping lower today. At the time of writing the benchmark index is down 0.15% to 6,719.8 points. Four shares that have fallen more than most today are listed below. He...

New Zealand’s medicines regulator has recommended the country fall in line with Australia’s new codeine restrictions, and pharmaceutical companies are backing the decision. Yesterday, Medsafe recommended that all medications containing code...

CSL Limited (ASX: CSL) will go down as one of the greatest growth stories of all time. The company has been unshakeable in its ability to deliver consistent earnings growth and shareholder value for more than 2 decades. But for many inves...

With populations around the world getting older and chronic disease burden increasing, demand for healthcare services continues to increase. I expect this trend to continue for several decades, which I feel makes the healthcare sector a gr...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has gone gangbusters, soaring more than 20% in the past 5 days, before dipping back slightly in yesterday’s trade to close down 1.87%. Paradigm is a late stage ASX-listed biotechn...

I think the mid cap space is a great place to look for buy and hold investment ideas. This is because I believe there are a good number of shares that have the potential to grow strongly over the next decade, potentially generating outsize...

Paradigm is repurposing the drug Pentosan Polysulfate Sodium (PPS) under the name ZILOSUL®.

The S&P/ASX 200 index has recovered from a spot of late morning weakness and is pushing higher in afternoon trade. At the time of writing the benchmark index is up a solid 0.4% to 6,795.4 points. Four shares that are climbing more than...

The Alcidion Group Ltd (ASX: ALC) share price has been a positive performer on Tuesday. In morning trade the healthcare technology company’s shares were up 8% to 20.5 cents at one stage. Why did the Alcidion share price surge higher? Inves...

Paradigm is repurposing the drug Pentosan Polysulfate Sodium (PPS) under the name ZILOSUL®.

Australia’s health care industry is one of the fastest growing industries in the country that is making substantial progress driven by new technological advancements. The country’s government is injecting billions of dollars into modernisin...

The Novita Healthcare Ltd (ASX: NHL) share price is down 7% to 9.1 cents today, but up around 8x from 1.1 cents on October 23 after the biotech handed investors some big news. On October 24 hardly known Novita told investors its TALi Detec...

In afternoon trade the S&P/ASX 200 index has given back its morning gains and dropped lower. At the time of writing the benchmark index is trading 0.2% lower at 6,714.3 points. Four shares that have not let that hold them back are list...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price was on form again on Thursday. The biopharmaceutical company’s shares pushed 4% higher to $2.93 on the day of its annual general meeting. This latest gain means the Paradigm share...

The biotech gained up to 5% by lunch on confirming FY20 milestones, including an early-2020 filing with the US FDA for an OA drug.

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

The Next Science Ltd (ASX: NXS) share price has slipped 5% to $2.52 today but investors shouldn’t be disheartened as the stock is still up 150% from its April 2019 $1 per share initial public offer price.  For the quarter ending September...

The Novita Healthcare Ltd (ASX: NHL) share price is now up around 4.5x or 350% since last week. That’s not a typo either as the early learning childhood technology business reported that its TALi Detect platform could be delivered via the...

The S&P/ASX 200 index is on course to start the week on a positive note. In afternoon trade the benchmark index is up 0.15% to 6,749.7 points. Four shares climbing more than most today are listed below. Here’s why they are storming hig...

It has been a very positive end to the week for the S&P/ASX 200 index. In afternoon trade the benchmark index is up a solid 0.65% to 6,737 points. Four shares that have climbed more than most today are listed below. Here’s why they are...

The IRB has followed the FDA in approving the submission to treat 10 ex NFL players with Paradigm’s trial drug Zilosul.

Paradigm Biopharmaceuticals (ASX: PAR) has been given the go-ahead by US regulators to treat 10 former NFL players with its pentosan polysulfate sodium (iPPS) drug, otherwise known as Zilosul. Following the successful US Food and Drug Admin...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has gone gangbusters in 2019 as wild investor excitement mounts over its Zilosul drug’s commercial potential. The biotech now has a market value around $516 million despite posting...

The Polynovo Ltd (ASX: PNV) share price is up 7% to $2.43 this lunchtime despite the biotech not releasing any specific news to the market. On September 23 the little-known surgical material business joined the S&P/ ASX200 (ASX: XJO) in...

The Orthocell Ltd (ASX: OCC) share price is up 25% to 50 cents today after the regenerative medicine researcher announced trial results showed its medical device CelGro® had helped quadriplegics regain arm and hand functions.  CelGro® is r...

Health care, being the dynamic sector, keep investors on their toes before injecting their funds. Vigilance to information is an important criterion that allows investors and market enthusiasts to capitalise money in the stocks. Variables p...

Massive legal settlements in the US have highlighted the scourge of opioid abuse, but Australian producer Palla Pharma is confident the drug class will remain the world's foremost pain medication. Meanwhile, Paradigm Pharmaceuticals present...

The All Ordinaries index was a strong performer on Tuesday, rising by a solid 0.8% to 6,853 points. This strong gain means the index is now trading close to its all-time high. Unsurprisingly, this positive form means a number of shares are...

Mesoblast limited (ASX: MSB) shares are locked in a trading halt today with the regenerative medicine business reportedly seeking to raise another $75 million according to news reports in the Australian Financial Review. Mesoblast has often...

Headlines are being made in the US today with a Republican Congressman expected to plead guilty to insider trading charges brought by the US securities regulator the SEC. Making the case unusual is that the micro-cap biotech in question is...

It's been 25 years since the Canberra Raiders have won a premiership. Sadly they knocked out my Bunnies on Friday night, but if we were going to lose to anyone I'm glad it was the Green Machine. Let's just hope they spank the Roosters on Su...

You may have heard about an opioid crisis over in the US; it was declared a public health emergency in 2017 amid 130 deaths every day from opioid-related drug overdoses and 2.1 million people with an opioid use disorder. In Australia, the p...

I’ve not bought many new companies on the local sharemarket over the last 12 months as most of any research efforts are directed towards the US these days, however, there are a few small-cap businesses on the local market worth watching. ...

The company’s data has been published in the peer-reviewed international scientific journal PLoS One

Health care industry Australian health care industry is not just on a strong growth path but also competes on the global scale. Health Care comprises of a dynamic sector including pharmaceuticals, medical devices, health insurance and hospi...

In afternoon trade the S&P/ASX 200 index is on course to start the week with a small gain. At the time of writing the benchmark index is up 0.15% to 6,726 points. Four shares that are climbing more than most today are listed below. Her...